Literature DB >> 1903547

Effect of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells.

C M Arundel-Suto1, S V Scavone, W R Turner, M J Suto, J S Sebolt-Leopold.   

Abstract

The modifying effects of PD 128763 (3,4-dihydro-5-methyl-1(2H)-isoquinolinone), a potent inhibitor of poly(adenosine-diphosphate (ADP)-ribose) polymerase, on radiation-induced cell killing were examined in Chinese hamster V79 cells. This compound has an IC50 value against the purified enzyme approximately 50X lower than 3-aminobenzamide (3-AB), a widely used specific inhibitor of the enzyme. Exposure of exponentially growing cells to a noncytotoxic concentration (0.5 mM) of PD 128763 for 2 h immediately following X irradiation increased their radiation sensitivity, modifying both the shoulder and the slope of the survival curve. When recovery from sublethal damage and potentially lethal damage was examined in exponential and plateau-phase cells, respectively, postirradiation incubation with 0.5 mM PD 128763 was found not only to inhibit both these processes fully, but also to enhance further the level of radiation-induced cell killing. This is in contrast to the slight effect seen with the less potent inhibitor, 3-AB. The results presented suggest that the mechanism of radiosensitization by PD 128763 is related to the potent inhibition of poly(ADP-ribose) polymerase by this compound.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1903547

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  9 in total

1.  Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.

Authors:  Yong Tang; Hossein A Hamed; Andrew Poklepovic; Yun Dai; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2012-05-17       Impact factor: 4.436

2.  Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken.

Authors:  A Ruf; J Mennissier de Murcia; G de Murcia; G E Schulz
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

3.  Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer.

Authors:  Rui Gao; Douglas K Price; William L Dahut; Eddie Reed; William D Figg
Journal:  Cancer Biol Ther       Date:  2010-07-01       Impact factor: 4.742

Review 4.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

5.  PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.

Authors:  Laurence Booth; Nichola Cruickshanks; Thomas Ridder; Yun Dai; Steven Grant; Paul Dent
Journal:  Cancer Biol Ther       Date:  2013-05       Impact factor: 4.742

6.  INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin.

Authors:  Kathryn A Mason; David Valdecanas; Nancy R Hunter; Luka Milas
Journal:  Invest New Drugs       Date:  2007-07-13       Impact factor: 3.850

7.  PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors.

Authors:  Valentina Perini; Michelle Schacke; Pablo Liddle; Salomé Vilchez-Larrea; Deborah J Keszenman; Laura Lafon-Hughes
Journal:  Int J Mol Sci       Date:  2020-11-05       Impact factor: 5.923

8.  Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.

Authors:  Helen E Bryant; Thomas Helleday
Journal:  Nucleic Acids Res       Date:  2006-03-23       Impact factor: 16.971

9.  Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

Authors:  K J Bowman; A White; B T Golding; R J Griffin; N J Curtin
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.